GF Fund Management
ACRS icon

GF Fund Management’s Aclaris Therapeutics ACRS Stock Holding History

GF Fund Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.6K Buy
2,779
+226
+9% +$1.29K ﹤0.01% 518
2026
Q2 		$13.5K Buy
2,553
+134
+6% +$598 ﹤0.01% 519
2026
Q1 		$9.07K Buy
2,419
+291
+14% +$982 ﹤0.01% 568
2025
Q4 		$6.4K Buy
+2,128
New +$5.38K ﹤0.01% 607

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Three Bridge Wealth Advisors
Three Bridge Wealth Advisors Los Altos, California $469M AUM 10.36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

GF Fund Management's ACRS Position: Q3 2026 in Review

GF Fund Management increased its Aclaris Therapeutics (ACRS) stake by 8.9% in Q3 2026, buying an estimated $1.29K and bringing the position to 2,779 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #518.

GF Fund Management first reported a position in ACRS in Q4 2025 and has held it in 4 quarters since. 52 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • GF Fund Management held 2,779 shares of Aclaris Therapeutics worth $14.6K as of Q3 2026.
  • GF Fund Management bought 226 Aclaris Therapeutics shares in Q3 2026, an estimated $1.29K.
  • Aclaris Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #518 holding.
  • GF Fund Management first reported a position in Aclaris Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 52 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.